Gene therapy company bluebird bio acquires Precision Genome Engineering
Bluebird bio Inc. (gene therapy for genetic and orphan diseases) acquired Precision Genome Engineering Inc. (aka Pregenen; gene editing and cell signaling technologies) for 408.7k bluebird shares up front plus 94.1k shares held back for 18 months (together worth $19.2mm), and the assumption of $4.9mm of current liabilities.
- Gene Therapy, Cell Therapy
- Full Acquisition
- Includes Contract
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Stock
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.